The risks of hepatitis B (HR = 4.3, 95% CI: 1.5–12.7) and TB (HR = 5.1, 95% CI: 2.0–13.6) reactivation also increased for patients with IBD who were treated with anti-TNF-α, especially among those in the high accumulated dosage group. The gene discussed is TNF; the disease is inflammatory bowel disease.